Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)

The National Institutes of Health (NIH) is seeking research to elucidate how HIV-induced immunometabolic alterations impact the immune response and increase risk for poor outcomes due to a second infection such as Mycobacterium tuberculosis (Mtb) or Hepatitis B Virus (HBV). The goal of this research is to define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and ultimately, TB and HBV disease progression. Key aspects of this opportunity include: * Research to understand the relationship between HIV-induced immunometabolic alterations and increased risk of TB or HBV * Investigation of how HIV-driven alterations to immunometabolism affect immune cell regulation and response to treatment * Elucidation of the impact of HIV-induced immunometabolic alterations on TB and HBV disease progression * Development of new treatments or therapies to prevent or treat TB and HBV in individuals with HIV